Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Oxford Nanopore tech used in 'groundbreaking' telomere study
(Sharecast News) - Oxford Nanopore took the wraps off a "groundbreaking" study using its technology on Friday, shedding light on the measurement of human telomeres - the protective caps at the ends of chromosomes crucial for genome integrity. The London-listed firm said the breakthrough, published in the journal Science, was a significant advancement in understanding the correlation between telomeres and age-related diseases, as well as cancer susceptibility.
Led by Nobel laureate Dr Carol Greider of UC Santa Cruz, the research represented the first successful attempt to precisely measure and profile telomere length using Oxford Nanopore's sequencing technology.
Dr Greider envisioned the telomeric regions, along with associated proteins, as potential targets for preventive healthcare interventions and drug discovery initiatives.
The company explained that decades of scientific inquiry, including research spearheaded by Dr Greider, established the pivotal role of telomeres in health and disease.
Short telomeres were linked to degenerative conditions, while long telomeres could predispose individuals to cancer.
Despite that understanding, the intricate mechanisms governing telomere length regulation had thus far remained elusive.
In the study, the team analysed telomere lengths in 147 individuals, uncovering a pattern where specific telomeres consistently exhibited either the shortest or longest lengths.
The observation suggested that certain chromosome ends with shorter telomeres could be implicated in triggering stem-cell failure, offering insights for further clinical investigation and potential drug development.
Central to the breakthrough was Oxford Nanopore's technology, which enabled the observation of long telomere-length reads at nearly single nucleotide resolution for the first time.
The firm said the capability had sparked a surge of interest in telomere-based research, exemplified by the development of a novel workflow called Telo-seq, jointly pioneered by Oxford Nanopore and the Karlseder lab at the Salk Institute for Biological Studies in November last year.
"Today marks a significant milestone not just for Oxford Nanopore but for the field of genomics," said chief executive officer Gordon Sanghera.
"This breakthrough illustrates that what you're missing matters in genomics, showcasing the benefits of richer insights to capture more types of genetic variation and unravel the mysteries of biology."
Sanghera said it was also a step towards new healthcare solutions, offering novel avenues for preventing and treating age-related diseases and cancer.
"We are proud to be at the forefront of this research, empowering scientists worldwide with tools that unlock unprecedented genomic insight."
At 1450 BST, shares in Oxford Nanopore Technologies were down 0.04% at 108.7p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.